IQVIA Holdings Inc. logo
IQVIA Holdings Inc. (IQV)
Compare

IQVIA Holdings Inc. (IQV) EV/Sales Ratio: 1.85x

popular:market cap|pe ratio|revenue|price history|total return

Is IQVIA Holdings Inc.’s EV/Sales ratio high or low?

IQVIA Holdings Inc.'s EV/Sales ratio of 1.85x is 48% below its 5-year average of 3.53x, near the low end of its 5-year range (1.66x–4.97x).

As of Thursday, June 11, 2026. 34.64% below its 12-month average of 2.83x.

EV/EBITDA|P/S Ratio|Revenue|All Metrics

IQV EV/Sales Ratio Chart

IQV EV/Sales Ratio
1.85x-29.92% 1Y
Zoom

IQV Average EV/Sales Ratio Chart

IQV Current vs Average EV/Sales Ratio Chart

IQV EV/Sales Ratio Metrics

EV/SALES RATIO

1.85x

EV/SALES RATIO AVG TTM

2.83x

EV/SALES RATIO AVG 3Y

3.22x

EV/SALES RATIO AVG 5Y

3.53x

EV/SALES RATIO AVG 10Y

3.46x

EV/SALES RATIO AVG 15Y

3.04x

EV/SALES RATIO AVG 20Y

3.04x

CURRENT VS TTM AVG

-34.64%

CURRENT VS 3Y AVG

-42.51%

CURRENT VS 5Y AVG

-47.59%

CURRENT VS 10Y AVG

-46.54%

CURRENT VS 15Y AVG

-39.07%

CURRENT VS 20Y AVG

-39.07%

IQV Competitors' EV/Sales Ratio

NAMEMARKET CAPEV/SALES RATIOTTM3Y5Y
IQVIA Holdings Inc. (IQV)$30.08B1.85x2.83x3.22x3.53x
Medline Inc. (MDLN)$30.90B1.39x1.60x1.60x1.60x
Biogen Inc. (BIIB)$28.94B3.26x2.79x3.30x3.58x
DexCom, Inc. (DXCM)$28.92B6.18x6.63x10.22x13.87x
Centene Corporation (CNC)$32.26B0.14x0.11x0.20x0.29x
Veeva Systems Inc. (VEEV)$26.31B7.65x12.50x13.33x15.70x
Zoetis Inc. (ZTS)$34.27B4.40x6.71x8.77x9.90x
Agilent Technologies, Inc. (A)$36.21B5.38x5.56x5.75x6.21x
Waters Corporation (WAT)$23.21B9.27x7.03x7.13x7.32x
Mettler-Toledo International Inc. (MTD)$22.82B6.13x7.35x7.51x8.18x

Understanding EV/Sales

Enterprise Value (EV) = Market Cap + Total Debt - Cash

Sales = Total Revenue (TTM)

EV/Sales is commonly used because:

  • It works for unprofitable companies where P/E doesn't apply
  • Revenue is harder to manipulate than earnings
  • It supports comparisons across companies at different profitability stages
  • It is frequently used for software and other revenue-growth-focused companies

Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.

IQVIA Holdings Inc. EV/Sales Ratio Formula & Definition

EV/Sales = Enterprise Value / Revenue (TTM)

Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

IQVIA Holdings Inc. EV/Sales Ratio FAQ

What is the EV/Sales ratio for IQVIA Holdings Inc. (IQV)?
The EV/Sales ratio for IQV stock is 1.85x.
Is IQVIA Holdings Inc.'s EV/Sales ratio high or low?
IQVIA Holdings Inc.'s EV/Sales ratio of 1.85x is 48% below its 5-year average of 3.53x, near the low end of its 5-year range (1.66x–4.97x).
What is the TTM average EV/Sales ratio for IQVIA Holdings Inc. (IQV)?
The TTM average EV/Sales ratio for IQV stock is 2.83x.
What is the 3Y average EV/Sales ratio for IQVIA Holdings Inc. (IQV)?
The 3Y average EV/Sales ratio for IQV stock is 3.22x.
What is the 5Y average EV/Sales ratio for IQVIA Holdings Inc. (IQV)?
The 5Y average EV/Sales ratio for IQV stock is 3.53x.
What is the 10Y average EV/Sales ratio for IQVIA Holdings Inc. (IQV)?
The 10Y average EV/Sales ratio for IQV stock is 3.46x.
What is the 15Y average EV/Sales ratio for IQVIA Holdings Inc. (IQV)?
The 15Y average EV/Sales ratio for IQV stock is 3.04x.
What is the 20Y average EV/Sales ratio for IQVIA Holdings Inc. (IQV)?
The 20Y average EV/Sales ratio for IQV stock is 3.04x.

IQVIA Holdings Inc. EV/Sales Ratio History

DATEEV/SALES RATIO
2026-06-111.85x
2026-06-101.87x
2026-06-091.91x
2026-06-081.88x
2026-06-051.88x
2026-06-041.92x
2026-06-031.87x
2026-06-021.85x
2026-06-011.92x
2026-05-291.87x
2026-05-281.86x
2026-05-271.70x
2026-05-261.66x
2026-05-221.72x
2026-05-211.72x
2026-05-201.76x
2026-05-191.78x
2026-05-181.77x
2026-05-151.73x
2026-05-141.75x
2026-05-131.77x
2026-05-121.79x
2026-05-111.78x
2026-05-081.83x
2026-05-071.83x
2026-05-061.81x
2026-05-051.81x
2026-05-042.57x
2026-05-012.53x
2026-04-302.54x
2026-04-292.52x
2026-04-282.55x
2026-04-272.60x
2026-04-242.58x
2026-04-232.56x
2026-04-222.72x
2026-04-212.72x
2026-04-202.73x
2026-04-172.73x
2026-04-162.68x
2026-04-152.75x
2026-04-142.72x
2026-04-132.68x
2026-04-102.63x
2026-04-092.65x
2026-04-082.69x
2026-04-072.67x
2026-04-062.67x
2026-04-022.70x
2026-04-012.69x
2026-03-312.67x
2026-03-302.62x
2026-03-272.60x
2026-03-262.66x
2026-03-252.62x
2026-03-242.62x
2026-03-232.63x
2026-03-202.62x
2026-03-192.62x
2026-03-182.63x
2026-03-172.65x
2026-03-162.61x
2026-03-132.61x
2026-03-122.59x
2026-03-112.68x
2026-03-102.67x
2026-03-092.75x
2026-03-062.71x
2026-03-052.75x
2026-03-042.75x
2026-03-032.70x
2026-03-022.71x
2026-02-272.75x
2026-02-262.67x
2026-02-252.58x
2026-02-242.61x
2026-02-232.58x
2026-02-202.62x
2026-02-192.66x
2026-02-182.67x
2026-02-172.60x
2026-02-132.64x
2026-02-122.66x
2026-02-112.75x
2026-02-102.81x
2026-02-092.92x
2026-02-062.87x
2026-02-052.79x
2026-02-043.03x
2026-02-033.04x
2026-02-023.34x
2026-01-303.33x
2026-01-293.38x
2026-01-283.43x
2026-01-273.44x
2026-01-263.43x
2026-01-233.38x
2026-01-223.42x
2026-01-213.45x
2026-01-203.36x
2026-01-163.41x
2026-01-153.45x
2026-01-143.45x
2026-01-133.45x
2026-01-123.44x
2026-01-093.46x
2026-01-083.47x
2026-01-073.48x
2026-01-063.44x
2026-01-053.37x
2026-01-023.27x
2025-12-313.27x
2025-12-303.30x
2025-12-293.29x
2025-12-263.29x
2025-12-243.28x
2025-12-233.27x
2025-12-223.26x
2025-12-193.22x
2025-12-183.24x
2025-12-173.23x
2025-12-163.23x
2025-12-153.26x
2025-12-123.24x
2025-12-113.28x
2025-12-103.25x
2025-12-093.20x
2025-12-083.25x
2025-12-053.28x
2025-12-043.27x
2025-12-033.29x
2025-12-023.28x
2025-12-013.31x
2025-11-283.32x
2025-11-263.34x
2025-11-253.34x
2025-11-243.30x
2025-11-213.27x
2025-11-203.18x
2025-11-193.19x
2025-11-183.19x
2025-11-173.17x
2025-11-143.22x
2025-11-133.25x
2025-11-123.23x
2025-11-113.20x
2025-11-103.14x
2025-11-073.11x
2025-11-063.12x
2025-11-053.11x
2025-11-043.12x
2025-11-033.15x
2025-10-313.18x
2025-10-303.18x
2025-10-293.19x
2025-10-283.20x
2025-10-273.27x
2025-10-243.30x
2025-10-233.30x
2025-10-223.27x
2025-10-213.28x
2025-10-203.21x
2025-10-173.13x
2025-10-163.14x
2025-10-153.11x
2025-10-143.13x
2025-10-133.12x
2025-10-103.06x
2025-10-093.11x
2025-10-083.08x
2025-10-073.09x
2025-10-063.13x
2025-10-033.15x
2025-10-023.12x
2025-10-013.12x
2025-09-302.97x
2025-09-292.86x
2025-09-262.85x
2025-09-252.82x
2025-09-242.87x
2025-09-232.93x
2025-09-222.94x
2025-09-192.94x
2025-09-182.97x
2025-09-172.93x
2025-09-162.93x
2025-09-152.92x
2025-09-122.94x
2025-09-112.97x
2025-09-102.90x
2025-09-092.96x
2025-09-082.94x
2025-09-052.94x
2025-09-042.90x
2025-09-032.91x
2025-09-022.90x
2025-08-292.98x
2025-08-282.95x
2025-08-272.95x
2025-08-262.94x
2025-08-252.94x
2025-08-222.98x
2025-08-212.92x
2025-08-202.99x
2025-08-192.99x
2025-08-182.99x
2025-08-152.98x
2025-08-142.96x
2025-08-132.97x
2025-08-122.92x
2025-08-112.86x
2025-08-082.85x
2025-08-072.84x
2025-08-062.83x
2025-08-052.90x
2025-08-042.89x
2025-08-012.88x
2025-07-312.92x
2025-07-302.98x
2025-07-293.02x
2025-07-283.05x
2025-07-253.07x
2025-07-243.09x
2025-07-233.01x
2025-07-222.94x
2025-07-212.64x
2025-07-182.66x
2025-07-172.69x
2025-07-162.64x
2025-07-152.63x
2025-07-142.66x
2025-07-112.69x
2025-07-102.72x
2025-07-092.68x
2025-07-082.71x
2025-07-072.68x
2025-07-032.70x
2025-07-022.71x
2025-07-012.69x
2025-06-302.63x
2025-06-272.63x
2025-06-262.63x
2025-06-252.64x
2025-06-242.64x
2025-06-232.60x
2025-06-202.60x
2025-06-182.59x
2025-06-172.59x
2025-06-162.65x
2025-06-132.62x
2025-06-122.65x
2025-06-112.64x
2025-06-102.65x
2025-06-092.59x
2025-06-062.57x
2025-06-052.51x
2025-06-042.52x
2025-06-032.46x
2025-06-022.42x
2025-05-302.43x

Showing the most recent 260 of 3,293 data points. The chart above shows the full history.

Related Metrics

EV/EBITDAP/S RatioRevenueAll Metrics

About IQVIA Holdings Inc.

IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific. The company's operations are structured into three key divisions: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides a suite of cloud-native applications, complete with implementation services, and offers real-world data solutions designed to empower life sciences and healthcare providers in generating and disseminating evidence crucial for informed decision-making and improving patient outcomes. This division also delivers strategic and operational consulting, including advanced analytics support and outsourcing of commercial processes. Furthermore, it supplies country-level performance metrics detailing pharmaceutical sales, prescribing trends, medical treatments, and promotional activities across diverse channels like retail, hospital, and mail order, with data granularity extending to regional, postal code, and individual prescriber levels. Focusing on clinical trials, the Research & Development Solutions segment offers project management, clinical monitoring, broader clinical trial support, virtual trial capabilities, and strategic planning and design services. It also manages an extensive network of laboratory services, encompassing central, genomic, bioanalytical, ADME, discovery, vaccine, and biomarker analyses. The Contract Sales & Medical Solutions segment is responsible for engaging healthcare professionals and patients, alongside providing scientific strategy and medical affairs support. IQVIA's diverse clientele includes pharmaceutical, biotechnology, medical device and diagnostic, and consumer health companies. The company maintains a strategic collaboration with HealthCore, Inc. Founded in 1982, the firm was formerly known as Quintiles IMS Holdings, Inc. before rebranding as IQVIA Holdings Inc. in November 2017. Its headquarters are located in Durham, North Carolina.

Durham, NC
89,000 employees
www.iqvia.com
Healthcare / Medical - Diagnostics & Research
Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Ari Bousbib
View full financials